Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg et al. · The Lancet · 2016
Cited by 2,198 works. doi:10.1016/s0140-6736(16)32455-2 Open-access PDF
Authors
- Arjun Vasant Balar
- Matthew D. Galsky
- Jonathan E. Rosenberg
- Thomas B. Powles
- Daniel Peter Petrylak
- Joaquim Bellmunt B
- Yohann Loriot
- Andrea Necchi
- Jean H. Hoffman-Censits
- José Luis Perez‐Gracia
- Nancy Ann Dawson
- Michiel S. van der Heijden
- Robert Dreicer
- Sandy Srinivas
- Margitta M. Retz
- Richard Wayne Joseph
- Alexandra Drakaki
- Ulka N. Vaishampayan
- Srikala S. Sridhar
- David I. Quinn
References
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma